Tigecycline, the first of a new class of antibiotics: The glycylcyclines;La tigeciclina, el primer antibiótico de una nueva clase: Las glicilciclinas

Revista Espanola de Quimioterapia

Volumn 20, Issue 1, 2007, Pages 19-35

  Boso Ribelles V ^a   Roma Sanchez E ^a   Salavert Lleti M ^a   Hernandez Marti V ^a   Poveda Andres J L ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; AZTREONAM; CILASTATIN PLUS IMIPENEM; DIGOXIN; LINEZOLID; MEROPENEM; MINOCYCLINE; POLYMYXIN B; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN; WARFARIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ABSCESS; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIOSTASIS; BACTEROIDES FRAGILIS; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DYSPEPSIA; DYSPNEA; ENTEROCOCCUS; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOPROTEINEMIA; INFECTION; INJECTION SITE EDEMA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INSOMNIA; LEUKOCYTOSIS; MIGRAINE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; NEISSERIA GONORRHOEAE; NONHUMAN; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHLEBITIS; PROTEUS MIRABILIS; PROTHROMBIN TIME; PRURITUS; PSEUDOMONAS AERUGINOSA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, BACTERIAL; GLYCYLGLYCINE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MINOCYCLINE;

EID: 34250904209     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Lázaro, E., Otero, J. Evolución del consumo y de la resistencia a antibióticos en España. Inf Ter Sist Nac Salud 2006; 30: 10-19.
2. Nathwani, D. Tigecycline: Clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25: 185-192.
3. Cuevas, O., Cercenado, E., Vindel, A. y cols. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: Five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004; 48: 4240-4245.
4. Hernández, J.R., Pascual, A., Cantón, R. y cols. Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21: 77-82.
5. Noskin, G.A. Tigecycline: A new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41 (Suppl. 5): S303-314.
6. Hoban, D.J., Bouchillon, S.K., Johnson, B.M., Johnson, J.L., Dowzicky, M.J. Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-227.
7. Livermore, D.M. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005; 56: 61161-61164.
8. Frampton, J.E., Curran, M.P. Tigecycline. Drugs 2005; 65: 2623-2635.
9. Zhanel, G.G., Homenuik, K., Nichol, K. y cols. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004; 64: 63-88.
10. Tygacil®. Ficha técnica. Wyeth Europa Ltd., 2006.
11. Informe Epar (Tygacil®) EMEA, 2006. Disponible en: www.emea. eu.int
12. Tigecycline (Drug Evaluation Monographs). Hn: Hutchison, T.A., Shahan, D.R. (Eds.). DRUGDEX® System. MICROMEDEX, Greenwood Village, Colorado, Vol. 129 (Edition expires 09/06).
13. Bergeron, J., Ammirati, M., Danley, D. y cols. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade tet(M)-and tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226-2228.
14. Bauer, G., Berens, C., Projan, S.J. y cols. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethyl-sulphate and drug-directed Fe(2+) cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-599.
15. Bradford, P.A. Tigecycline: A first in class glycylcycline. Clin Microb News 2004; 26: 163-168.
16. Gobernado, M. Resistencias bacterianas y un nuevo antibiótico: Tigeciclina. Rev Esp Quimioterap 2006; 19: 209-219.
17. Bradford, P.A., Weaver-Sands, D.T., Petersen, P.J. y cols. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: S315-332.
18. Gales, A.C., Jones, R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
19. Bouchillon, S.K., Hoban, D.J., Johnson, B.M. y cols. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005; 51: 291-295.
20. Low, D.E., Kreiswirth, B.N., Weiss, K. y cols. Activity of GAR-936 and other antimicrobial agents against North American isolates of Staphylococcus aureus. Int J Antimicrob Agents 2002; 20: 220-222.
21. Milatovic, D., Schmitz, F.J., Verhoef, J. y cols. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-404.
22. Zhang, Y.Y., Zhou, L., Zhu, D.M. y cols. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 2004; 50: 267-281.
23. Boucher, H.W., Wennersten, C.B., Eliopoulos, G.M. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000; 44: 2225-2229.
24. Betriu, C., Rodríguez-Avial, I., Sánchez, B.A., Gómez, M., Picazo, J.J. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50: 758-759.
25. Cercenado, E., Cereenado, S., Bouza, E. In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob Agents Chemother 2003; 47: 2644-2645.
26. Rodríguez-Avial, I., Rodríguez-Avial, C., López, O., Culebras, E., Picazo, J.J. In vitro activity of tigecycline (GAR-936) and other antimicrobials against tetracycline- and ciprofloxacin-resistant Campylobacter clinical isolates. Int J Antimicrob Agents 2006; 27: 303-306.
27. Jacobus, N.V., McDermott, L.A., Ruthazer, R., Snydman, D.R. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004; 48: 1034-1036.
28. Edlund, C., Nord, C.E. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6: 159-163.
29. Wallace, R.J., Brown-Elliott, B.A., Crist, C.J., Mann, L., Wilson, R.W. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-3167.
30. Kenny, G.E., Cartwright, F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-2608.
31. Roblin, P.M., Hammerschlag, M.R. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16: 61-63.
32. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on tigecycline. Clin Microbiol Infect 2006; 12: 1147-1149.
33. Fritsche, T.R., Sader, H.S., Stilwell, M.G., Dowzicky, M.J., Jones, R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis. 2005; 52: 195-201.
34. Pachón-Ibáñez, M.E., Jiménez-Mejías, M.E., Pichardo, C., Llanos, A.C., Pachón, J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 2004; 48: 4479-4481.
35. Betriu, C., Rodríguez-Avial, I., Sánchez, B.A. y cols. In vitro activities of tigecycline (GAR-936) against recently isolated bacteria in Spain. Antimicrob Agents Chemother 2002; 46: 892-895.
36. Betriu, C., Culebras, E., Gómez, M. y cols. In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 2005; 56: 349-352.
37. Stein, G.E., Craig, W.A. Tigecycline: A critical analysis. Clin Infect Dis 2006 15; 43: 518-524.
38. Fluit, A.C., Florijn, A., Verhoef, J., Milatovic, D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005; 49: 1636-1638.
39. Petersen, P.J., Jacobus, N.V., Weiss, W.J., Sum, P.E., Testa, R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-744.
40. Ruzin, A., Keeney, D., Bradford, P.A. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791-793.
41. Dean, C.R., Visalli, M.A., Projan, S.J. y cols. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-978.
42. Yang, W., Moore, I.F., Koteva, K.P. y cols. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem 2004; 279: 52346-52352.
43. Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41 (Suppl. 5): S333-340.
44. Tygacil®. Monografía técnica del producto. Wyeth Europa Ltd., 2006.
45. Sun, H.K., Ong, C.T., Umer, A. y cols. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49: 1629-1632.
46. Ong, C.T., Babalola, C.P., Nightingale, C.H. y cols. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005; 56: 498-501.
47. Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-229.
48. Van Ogtrop, M.L., Andes, D., Stamstad, T.J. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943-949.
49. Mikels, S.M., Lenoy, E.B., Allen, W. y cols. Therapeutic efficacy of GAR-936, a novel glycylcycline, in murine infection models. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego (CA) 1998; 266.
50. Petersen, P.J., Weiss, W.J., Labthavikul, P. y cols. The post-antibiotic effect and time-kill kinetics of the glycylcyclines, GAR-936 (TBG-MI-NO) and PAM-MINO. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego (CA) 1998; 266.
51. Hoellman, D.B., Pankuch, G.A., Jacobs, M.R. y cols. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and resis tant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-1088.
52. Stein, G.E. Safety of newer parenteral antibiotics. Clin Infect Dis 2005; 41 (Suppl. 5): S293-302.
53. Breedt, J., Teras, J., Gardovskis, J. y cols., Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005: 49: 4658-4666.
54. Sacchidanand, S., Penn, R.L., Embil, J.M. y cols. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-261.
55. Oliva, M.E., Rekha, A., Yellin, A. y cols., Tigecycline 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials. gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5: 88.
56. Postier, R.G., Green, S.L., Klein, S.R. y cols. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-714.
57. Murray, J., Wilson, S., Klein, S. y cols. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago (IL) 2004; 416.
58. Ellis-Grosse, E.J., Babinchak, T. Dartois, N., Rose, G., Loh, E., Tigecycline 300 cSSSI Study Group, Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 (Suppl. 5): S341-353.
59. Babinchak, T., Ellis-Grosse, E., Dartois, N., Rose, G.M., Loh, E., Tigecycline 301 Study Group, Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis. 2005; 41 (Suppl. 5): S354-367.
60. Mallick, R., Solomon, S. The duration of hospitalization (length of stay) in patients hospitalized with complicated skin and skin structure infections: Identifying clinical and microbiological risk factors in a comparison of tigecycline with vancomycin/aztreonam. 15th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic 2005; abstr. P1181.
61. Yu, H., Mallick, R., Weber, D.J. Duration of antibiotic treatment in hospitalized patients with complicated skin and skin structure infections (cSSSI): Findings from a clinical study comparing tigecycline and vancomycin/aztreonam. International Society for Pharmacoeconomics and Outcomes Research, 10th Annual Meeting. Washington, DC 2005; Poster PIN3.
62. Tellado, J.M., Sitges-Serra, A., Barcenilla, F. y cols. Pautas de tratamiento antibiótico empírico de las infecciones intraabdominales. Emergencias 2005; 17: 221-227.
63. Peleg, A.Y., Potoski, B.A., Rea, R. y cols. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother 2007; 59: 128-131.